Author:
Galipeau Heather J,Verdu Elena F
Subject
Gastroenterology,Hepatology
Reference10 articles.
1. Current and emerging therapies for coeliac disease;Kivelä;Nat Rev Gastroenterol Hepatol,2021
2. Real-world gluten exposure in patients with celiac disease on gluten-free diets, determined from gliadin immunogenic peptides in urine and fecal samples;Stefanolo;Clin Gastroenterol Hepatol,2021
3. Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated phase 2 randomised, double-blind, placebo-controlled study;Tye-Din;Lancet Gastroenterol Hepatol,2023
4. Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies;Goel;Lancet Gastroenterol Hepatol,2017
5. Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease;Tye-Din;Aliment Pharmacol Ther,2019